It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A snapshot of the year-to-date total market return for 2024, outlining performance drivers and practical implications for investors.
28,420 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
A Gold.com board director sold a sizable stake as bullion endured its worst week in decades. This article explains wh...
As AI fuels data growth, Silicon Motion Technology stands out in the memory controller niche. This article breaks dow...
On Oct. 14, smart retirees take one afternoon to protect cash flow and simplify their finances. This guide lays out a...
Ericsson's 2026 earnings trajectory hinges on 5G expansion, services, and software. This guide breaks down what to wa...
Choosing between broad tech exposure and a semiconductor focus can shape your portfolio’s risk and return. This guide...
A Hollywood anecdote offers surprisingly practical money lessons. This article translates the idea behind paul rudd s...
Investing in biotech can be bold. This piece lays out practical scenarios for what much could $1,000 invested in Viki...
Eating out is a daily ritual for many families. This guide shows you how to choose credit card dining rewards that ac...
As Boyd Gaming nears its July 23 earnings, traders are weighing a potential 17.2% upside fueled by a disciplined buyb...
A real-world scenario shows how misreporting income can unlock large public aid streams. Learn how programs gauge ear...